DOVA: Dova Pharmaceuticals, Inc. - Summary | Jitta

Dova Pharmaceuticals, Inc.

NASDAQ:DOVA

Notice
Stock data is unavailable or the company’s delisted.
Price
$28.04
Loss Chance
58.4%
0.75JITTA SCORE
100.00%Over Jitta Line
Jitta Ranking
Sorry, the data is not yet available for this stock.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (16)
Recent Business Performance (50)
Financial Strength (0)
Return to Shareholders (0)
Competitive Advantage (0)
Jitta Signs
Recent Business PerformanceEarning Growth Last Year
Recent IPOLess than 3 years
Key Stats
Jitta Score
Jitta Line
0.75
100.00%
3.05
95.90%
Pharmaceuticals
4.44
8.42%
2.69
94.10%
5.18
39.71%
COMPANY DESCRIPTION
Dova Pharmaceuticals, Inc., a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company’s lead product candidate is DOPTELET that is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease scheduled to undergo a procedure. It also develops DOPTELET for the treatment of chronic immune thrombocytopenia and chemotherapy-induced thrombocytopenia. Dova Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Durham, North Carolina. As of November 12, 2019, Dova Pharmaceuticals, Inc. operates as a subsidiary of Swedish Orphan Biovitrum AB (publ).